It appears that Amgen, Inc.’s first-to-market KRAS G12C inhibitor Lumakras (sotorasib) has the data it needs for full approval in the US after the drug succeeded in a Phase III clinical trial in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study is meant to serve as a confirmatory trial following accelerated approval of Lumakras in May 2021 as a second-line treatment.
Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial
Detailed Results To Be Presented Later
Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.
More from Clinical Trials
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.